Skip to main content
SpringerLink
Log in

The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond

  • Leading Article
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Prescription medication abuse, particularly of opioids, remains a serious public health problem. Many socioeconomic and healthcare system factors have contributed to the resulting epidemic of prescription opioid abuse. As the scope of this epidemic became evident, efforts to make abuse-deterrent formulations (ADFs) began, and many ADFs are under development. In January 2013, the US Food and Drug Administration (FDA) issued a Draft Guidance outlining the categories of studies needed for evaluating the abuse-deterrent properties of ADF opioids (e.g., pre-market in vitro, pharmacokinetic and abuse potential studies, and post-marketing studies) and the four potential label claims that might be made about the products. Studies to be conducted are those required for approval, those that might be included as data in the label (implicit claims), and those that would be required to merit a specific explicit claim—Tier 1, 2, 3, or 4. In the context of the Guidance, new ADFs need to consider the unique features of their technology, market size, comparator products, actual routes and methods of abuse, the targeted health consequences of abuse, pricing and reimbursement, the impact of other interventions to decrease abuse, and the challenges in doing post-market studies. ADFs will not stop prescription opioid drug abuse; however, easily tampered formulations should not contribute to the problem. All extended-release (ER) opioids and other abusable drugs should have abuse-deterrent properties. Immediate-release (IR) opioids should also be formulated with abuse-deterrent properties, because abuse of IR opioids is a more common and serious problem than that of ER opioids. Maximum dosage strengths of ER opioids should also be limited. Finally, the current situation, where non-abuse-deterrent ER opioids exist concurrently on the market is extremely problematic from a public health policy perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Manchikanti L, Helm S, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9–38.

    PubMed  Google Scholar 

  2. Substance Abuse Mental Health Services. Results from the 2012 national survey on drug use and health: summary of national findings. Rockville: Substance Abuse and Mental Health Services Administration; 2013.

    Google Scholar 

  3. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657–9.

    Article  CAS  PubMed  Google Scholar 

  4. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers. United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;60(43):1487–92.

  5. The DAWN Report: highlights of the 2011 drug abuse warning network (DAWN) findings on drug-related emergency department visits. Rockville; Substance Abuse and Mental Health Services Administration, Center for Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2013.

  6. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657–67.

    Article  PubMed  Google Scholar 

  7. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw. 2003;1(3):423–8.

    PubMed  Google Scholar 

  8. Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23(4):1–9.

    Article  PubMed  Google Scholar 

  9. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205–17.

    Article  PubMed  Google Scholar 

  10. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011;8:1477–7517.

    Google Scholar 

  11. Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351–8.

    Article  CAS  PubMed  Google Scholar 

  12. Butler SF, Black RA, Serrano JM, Wood ME, Budman SH. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity. J Opioid Manage. 2010;6(4):239–41, 246–52.

    Article  Google Scholar 

  13. Food and Drug Administration. Guidance for Industry: abuse-deterrent opioids—evaluation and labeling (draft guidance). Jan 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf. Accessed 5 Jun 2014.

  14. Fischer B, Bibby M, Bouchard M. The global diversion of pharmaceutical drugsnon-medical use and diversion of psychotropic prescription drugs in North America: a review of sourcing routes and control measures. Addiction (Abingdon, England). 2010;105(12):2062–70.

    Article  Google Scholar 

  15. Surratt HL, O’Grady C, Kurtz SP, Stivers Y, Cicero TJ, Dart RC, et al. Reductions in prescription opioid diversion following recent legislative interventions in Florida. Pharmacoepidemiol Drug Saf. 2014;23(3):314–20.

    Article  PubMed  Google Scholar 

  16. Havens JR, Leukefeld CG, Deveaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014;139:9–17.

    Article  CAS  PubMed  Google Scholar 

  17. Purdue Pharma. Citizen petition, immediate-release opioid analgesics. 2014.

  18. Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep. 1987;102(4):426–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  19. Food and Drug Administration. Center for Drug Evaluation and Research Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM), Hilton Washington DC North/Gaithersburg, The Ballrooms, 620 Perry Parkway, Gaithersburg, Maryland, October 21–22, 2010. Draft Questions for the Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM230104.pdf. Accessed 18 Aug 2014.

  20. Food and Drug Administration. CDER 2008 Meeting Documents. http://www.fda.gov/ohrms/dockets/ac/cder08.html. Accessed 18 Aug 2014.

  21. Food and Drug Administration. 2009 Meeting Materials, Drug Safety and Risk Management Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm126014.htm. Accessed 18 Aug 2014.

  22. Food and Drug Administration. Guidance for Industry: assessment of abuse potential of drugs (draft guidance). Jan 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. Accessed 5 Jun 2014.

  23. Food and Drug Administration. Anesthetic and Life Support Drugs Advisory Committee back-up slides. 22 Apr 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM210856.pdf. Accessed 18 Aug 2014.

  24. Food and Drug Administration. Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, October 21–22 2010, Hilton Washington DC North/Gaithersburg, 620 Perry Parkway, Gaithersburg, Maryland. Summary minutes. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM236242.pdf. Accessed 18 Aug 2014.

  25. College on Problems of Drug Dependence. Workshop Assessment of abuse-deterrent and tamper-resistant technologies, Part II: new directions. June 16th, 2013. http://www.cpdd.vcu.edu/Pages/Meetings/Meetings_PDFs/2013CPDDprogrambook.pdf. Accessed 11 Sep 2014.

  26. Food and Drug Administration. Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (DSaRM) open session, September 24, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM187082.pdf. Accessed 5 Jun 2014.

  27. Colucci SV, Perrino PJ, Shram M, Bartlett C, Wang Y, Harris SC. Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig. 2014;34(6):421–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011;11(3):259–75.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Abreu ME, Bigelow GE, Fleisher L, Walsh SL. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl). 2001;154(1):76–84.

    Article  CAS  PubMed  Google Scholar 

  30. de Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology (Berl). 1992;107(2–3):352–8.

    Article  PubMed  Google Scholar 

  31. Harris S, Colucci S, Perrino P, et al. Effects of various tampering methods on exposure to oxycodone in healthy subjects [poster no. 78]. 74th meeting of the College on Problems of Drug Dependence; 9–14 Jun 2012; Palm Springs.

  32. Perrino PJ, Colucci SV, Apseloff G, Harris SC. Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin® tablets compared with original OxyContin® tablets in healthy adults. Clin Drug Investig. 2013;33(6):441–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12(4):618–31.

    Article  PubMed  Google Scholar 

  34. Chapman CR, Hill HF, Saeger L, Gavrin J. Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain. Pain. 1990;43(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  35. Fedder IL, Vlasses PH, Mojaverian P, Rocci ML, Rotmensch HH, Swanson BN, et al. Relationship of morphine-induced miosis to plasma concentration in normal subjects. J Pharm Sci. 1984;73(10):1496–7.

    Article  CAS  PubMed  Google Scholar 

  36. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther. 2003;74(6):543–54.

    Article  CAS  PubMed  Google Scholar 

  37. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461–79.

    Article  CAS  PubMed  Google Scholar 

  38. Wang Y, Perrino P, Schoedel K, Geoffroy P, Colucci S, Harris SC. Abuse potential of chewed or intact oxycodone/naloxone (OXN) tablets in methadone-stabilized, opioid-dependent subjects when administered orally [abstract]. American Society of Pain Educators’ Pain Week; 3–6 Sep 2013; Las Vegas.

  39. Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Benedek IH, Comer SD. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126(1–2):206–15.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiology and drug safety. 2013;22(12):1274–82.

    Article  CAS  PubMed  Google Scholar 

  41. McNaughton EC, Coplan PM, Black RA, Weber SE, Chilcoat HD, Butler SF. Monitoring of internet forums to evaluate reactions to the introduction of reformulated oxycontin to deter abuse. J Med Internet Res. 2014;16(5):e119.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Severtson SG, Bartelson BB, Davis JM, Muñoz A, Schneider MF, Chilcoat H, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122–30.

    Article  PubMed  Google Scholar 

  43. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–9.

    Article  CAS  PubMed  Google Scholar 

  44. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA psychiatry. 2014;71(7):821–6.

    Article  PubMed  Google Scholar 

  45. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-46, HHS publication no. (SMA) 13-4795. Rockville: Substance Abuse and Mental Health Services Administration; 2013. http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.pdf. Accessed 18 Aug 2014.

  46. Food and Drug Administration. FDA/CDER to Endo Pharmaceuticals Inc. Petition Denial, Docket ID: FDA-2012-P-0895. 2012. https://www.regulationjs.gov/#!docketDetails. Accessed 4 Jun 2014.

  47. Pasquale MK, Joshi AV, Dufour R, Schaaf D, Mardekian J, Andrews GA, et al. Cost drivers of prescription opioid abuse in commercial and medicare populations. Pain Pract. 2014;14(3):E116–25.

    Article  PubMed  Google Scholar 

  48. Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17(4):279–87.

    Article  PubMed  Google Scholar 

  49. White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469–79.

    PubMed  Google Scholar 

  50. Conference Board of Canada. Evolving Science of Abuse Deterrence, Ottawa, Canada April 30, 2014. 2014.

  51. Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2014;54(4):468–77.

    Article  PubMed  Google Scholar 

  52. Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;27(9):808–16.

    Article  CAS  PubMed  Google Scholar 

  53. Purdue Pharma LP. Oxycontin prescribing information. Stamford: Purdue Pharma LP; 2014.

  54. Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain. 2012;13(1):90–9.

    Article  CAS  PubMed  Google Scholar 

  55. Janssen Pharmaceuticals Inc. Nucynta® ER (tapentadol extended-release oral tablets) prescribing information. Titusville: Janssen Pharmaceuticals Inc.; 2014.

  56. Cepeda MS, Fife D, Ma Q, Ryan PB. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study. J Pain. 2013;14(10):1227–41.

    Article  CAS  PubMed  Google Scholar 

  57. Dart RC, Bartelson BB, Adams EH. Non-medical use of tapentadol immediate release by college students. Clin J Pain. 2014;30(8):685–92.

  58. Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH. Assessment of the abuse of tapentadol immediate release: the first 24 months. J Opioid Manage. 2012;8(6):395–402.

    Article  Google Scholar 

  59. Mallinckrodt Brand Pharmaceuticals Inc. Exalgo® (hydromorphone hydrochloride extended-release tablets) prescribing information. Hazelwood: Mallinckrodt Brand Pharmaceuticals Inc.; 2014.

  60. Shram MJ, Sathyan G, Khanna S, Tudor IC, Nath R, Thipphawong J, et al. Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25–33.

  61. Pfizer Inc. Oxecta® (oxycodone hydrochloride USP tablets) prescribing information. New York: Pfizer Inc.; 2014.

  62. Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, et al. Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users. J Opioid Manage. 2012;8(5):315–27.

    Article  Google Scholar 

  63. Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEDA (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year. J Opioid Manage. 2012;8(2):115–25.

    Article  Google Scholar 

  64. Pfizer Inc. EMBEDA® (morphine sulfate and naltrexone hydrochloride extended release capsules) prescribing Information. New York: Pfizer Inc.; 2014.

  65. Johnson F, Setnik B. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. Pain Physician. 2011;14(4):391–406.

    PubMed  Google Scholar 

  66. Jones J, Sokolowska M, Setnik B, Romach M, F J, Stauffer J, et al. Pharmacodynamic (drug liking) effects of ALO-01, an investigational extended-release opioid formulation containing morphine sulfate and sequestered naltrexone, whole vs crushed. 24th annual meeting of the American Academy of Pain Medicine 2014.

  67. Sanofi-Aventis US LLC. Talwin Nx (pentazocine and naloxone hydrochlorides, USP tablets) prescribing information. Bridgewater: Sanofi-Aventis US LLC; 2014.

  68. Senay EC, Clara JR. Impact of Talwin NX. NIDA Res Monogr. 1984;55:170–7.

    CAS  PubMed  Google Scholar 

  69. Reckitt Benckiser Pharmaceuticals Inc. Suboxone® (buprenorphine and naloxone sublingual film) prescribing information. Richmond: Reckitt Benckiser Pharmaceuticals Inc.; 2014.

  70. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther. 2002;303(2):695–703.

  71. Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105(4):709–18.

  72. Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, et al. Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. Addict Biol. 2014. doi:10.1111/adb.12163.

Download references

Acknowledgments

EM Sellers, MJ Shram, and KA Schoedel declare no relevant conflicts of interest. No sources of funding were used to support the writing of this manuscript.

Author information

Authors and Affiliations

  1. DL Global Partners, Inc., 78 Baby Point Crescent, Toronto, ON, M6S 2C1, Canada

    Edward M. Sellers

  2. University of Toronto, Toronto, ON, Canada

    Edward M. Sellers & Megan J. Shram

  3. Altreos Research Partners, Inc., Toronto, ON, Canada

    Megan J. Shram & Kerri A. Schoedel

Authors
  1. Edward M. Sellers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan J. Shram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kerri A. Schoedel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edward M. Sellers.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sellers, E.M., Shram, M.J. & Schoedel, K.A. The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond. Pharm Med 28, 317–327 (2014). https://doi.org/10.1007/s40290-014-0067-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-014-0067-1

Keywords

Search

Navigation